CA2557181A1 - Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de facon differentielle dans les cellules musculaires - Google Patents

Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de facon differentielle dans les cellules musculaires Download PDF

Info

Publication number: CA2557181A1
Authority: CA; Canada
Prior art keywords: protein; human; mouse; gene; expression
Prior art date: 2004-02-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002557181A

Other languages

English (en)

Inventor

John J. Kopchick

Karen T. Coschigano

Keith S. Boyce

Andres Kriete

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ohio University

Cogenics Icoria Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-26

Filing date

2005-02-24

Publication date

2005-09-09

2005-02-24 Application filed by Individual filed Critical Individual

2005-09-09 Publication of CA2557181A1 publication Critical patent/CA2557181A1/fr

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 552
208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract description 77
206010060378 Hyperinsulinaemia Diseases 0.000 title abstract description 23
230000003451 hyperinsulinaemic effect Effects 0.000 title abstract description 23
201000008980 hyperinsulinism Diseases 0.000 title abstract description 23
230000004224 protection Effects 0.000 title abstract description 10
238000003745 diagnosis Methods 0.000 title abstract description 5
210000000663 muscle cell Anatomy 0.000 title description 8
102000004169 proteins and genes Human genes 0.000 claims abstract description 239
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 115
241000282414 Homo sapiens Species 0.000 claims abstract description 111
210000003205 muscle Anatomy 0.000 claims abstract description 49
230000000910 hyperinsulinemic effect Effects 0.000 claims abstract description 40
239000005557 antagonist Substances 0.000 claims abstract description 23
230000014509 gene expression Effects 0.000 claims description 106
108090000765 processed proteins & peptides Proteins 0.000 claims description 80
108090000144 Human Proteins Proteins 0.000 claims description 63
102000003839 Human Proteins Human genes 0.000 claims description 63
238000000034 method Methods 0.000 claims description 62
230000002349 favourable effect Effects 0.000 claims description 46
102000004196 processed proteins & peptides Human genes 0.000 claims description 41
239000003795 chemical substances by application Substances 0.000 claims description 37
210000001519 tissue Anatomy 0.000 claims description 34
108090000143 Mouse Proteins Proteins 0.000 claims description 30
239000012634 fragment Substances 0.000 claims description 23
108020004999 messenger RNA Proteins 0.000 claims description 22
150000007523 nucleic acids Chemical class 0.000 claims description 21
238000012216 screening Methods 0.000 claims description 21
102000039446 nucleic acids Human genes 0.000 claims description 19
108020004707 nucleic acids Proteins 0.000 claims description 19
229920001184 polypeptide Polymers 0.000 claims description 18
239000013598 vector Substances 0.000 claims description 13
108091093037 Peptide nucleic acid Proteins 0.000 claims description 11
108010043958 Peptoids Proteins 0.000 claims description 11
239000003550 marker Substances 0.000 claims description 10
230000009870 specific binding Effects 0.000 claims description 10
239000013604 expression vector Substances 0.000 claims description 5
230000000692 anti-sense effect Effects 0.000 claims description 4
230000001681 protective effect Effects 0.000 claims description 4
239000000427 antigen Substances 0.000 claims description 3
108091007433 antigens Proteins 0.000 claims description 3
102000036639 antigens Human genes 0.000 claims description 3
210000001124 body fluid Anatomy 0.000 claims 2
239000010839 body fluid Substances 0.000 claims 2
210000005260 human cell Anatomy 0.000 claims 1
238000004458 analytical method Methods 0.000 abstract description 20
235000018102 proteins Nutrition 0.000 description 209
241000699666 Mus <mouse, genus> Species 0.000 description 162
108020004414 DNA Proteins 0.000 description 148
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 118
210000004027 cell Anatomy 0.000 description 83
241000699670 Mus sp. Species 0.000 description 74
102000004877 Insulin Human genes 0.000 description 60
108090001061 Insulin Proteins 0.000 description 60
229940125396 insulin Drugs 0.000 description 59
230000000875 corresponding effect Effects 0.000 description 57
239000000523 sample Substances 0.000 description 54
230000000694 effects Effects 0.000 description 53
108020004635 Complementary DNA Proteins 0.000 description 52
238000010804 cDNA synthesis Methods 0.000 description 50
235000001014 amino acid Nutrition 0.000 description 49
239000002299 complementary DNA Substances 0.000 description 49
229940024606 amino acid Drugs 0.000 description 48
150000001413 amino acids Chemical class 0.000 description 48
230000027455 binding Effects 0.000 description 48
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 48
238000003556 assay Methods 0.000 description 45
239000000047 product Substances 0.000 description 45
238000009396 hybridization Methods 0.000 description 44
201000010099 disease Diseases 0.000 description 41
229910052760 oxygen Inorganic materials 0.000 description 38
230000006399 behavior Effects 0.000 description 36
239000008103 glucose Substances 0.000 description 33
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
239000012491 analyte Substances 0.000 description 29
241001465754 Metazoa Species 0.000 description 28
229910052770 Uranium Inorganic materials 0.000 description 27
230000001105 regulatory effect Effects 0.000 description 27
235000005911 diet Nutrition 0.000 description 26
230000037213 diet Effects 0.000 description 26
230000004048 modification Effects 0.000 description 26
238000012986 modification Methods 0.000 description 26
229910052757 nitrogen Inorganic materials 0.000 description 26
108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
150000001875 compounds Chemical class 0.000 description 25
239000003153 chemical reaction reagent Substances 0.000 description 24
239000003814 drug Substances 0.000 description 24
108020003175 receptors Proteins 0.000 description 23
102000005962 receptors Human genes 0.000 description 23
-1 siloxanes Chemical class 0.000 description 23
238000006467 substitution reaction Methods 0.000 description 23
206010022489 Insulin Resistance Diseases 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 21
210000004369 blood Anatomy 0.000 description 21
239000008280 blood Substances 0.000 description 21
238000011282 treatment Methods 0.000 description 21
229940079593 drug Drugs 0.000 description 20
210000003734 kidney Anatomy 0.000 description 20
208000008589 Obesity Diseases 0.000 description 19
230000004913 activation Effects 0.000 description 19
235000020824 obesity Nutrition 0.000 description 19
230000004071 biological effect Effects 0.000 description 18
230000036961 partial effect Effects 0.000 description 18
239000000126 substance Substances 0.000 description 18
238000003786 synthesis reaction Methods 0.000 description 17
101000775570 Homo sapiens Cell death activator CIDE-A Proteins 0.000 description 16
230000001965 increasing effect Effects 0.000 description 16
210000002027 skeletal muscle Anatomy 0.000 description 16
102100032141 Cell death activator CIDE-A Human genes 0.000 description 15
230000006907 apoptotic process Effects 0.000 description 15
230000008859 change Effects 0.000 description 15
210000000056 organ Anatomy 0.000 description 15
108091028043 Nucleic acid sequence Proteins 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 14
229910052799 carbon Inorganic materials 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 14
238000011161 development Methods 0.000 description 14
230000018109 developmental process Effects 0.000 description 14
230000035772 mutation Effects 0.000 description 14
241000124008 Mammalia Species 0.000 description 13
230000000295 complement effect Effects 0.000 description 13
229940088598 enzyme Drugs 0.000 description 13
229910052739 hydrogen Inorganic materials 0.000 description 13
230000011664 signaling Effects 0.000 description 13
241000196324 Embryophyta Species 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
241000282412 Homo Species 0.000 description 12
239000002253 acid Substances 0.000 description 12
108010038807 Oligopeptides Proteins 0.000 description 11
102000015636 Oligopeptides Human genes 0.000 description 11
241000700159 Rattus Species 0.000 description 11
230000032683 aging Effects 0.000 description 11
230000004075 alteration Effects 0.000 description 11
235000009200 high fat diet Nutrition 0.000 description 11
239000003446 ligand Substances 0.000 description 11
210000004185 liver Anatomy 0.000 description 11
239000002773 nucleotide Substances 0.000 description 11
125000003729 nucleotide group Chemical group 0.000 description 11
230000037361 pathway Effects 0.000 description 11
238000002372 labelling Methods 0.000 description 10
241000894007 species Species 0.000 description 10
235000000346 sugar Nutrition 0.000 description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
102100020948 Growth hormone receptor Human genes 0.000 description 9
230000007423 decrease Effects 0.000 description 9
230000003247 decreasing effect Effects 0.000 description 9
238000013467 fragmentation Methods 0.000 description 9
238000006062 fragmentation reaction Methods 0.000 description 9
239000000203 mixture Substances 0.000 description 9
210000000496 pancreas Anatomy 0.000 description 9
108010085238 Actins Proteins 0.000 description 8
102000007469 Actins Human genes 0.000 description 8
241000700605 Viruses Species 0.000 description 8
125000004429 atom Chemical group 0.000 description 8
230000008901 benefit Effects 0.000 description 8
229940049706 benzodiazepine Drugs 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
230000004927 fusion Effects 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
125000005647 linker group Chemical group 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000012528 membrane Substances 0.000 description 8
229910052698 phosphorus Inorganic materials 0.000 description 8
230000007017 scission Effects 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
230000014616 translation Effects 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 7
239000011324 bead Substances 0.000 description 7
230000037396 body weight Effects 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
108020001507 fusion proteins Proteins 0.000 description 7
102000037865 fusion proteins Human genes 0.000 description 7
230000003993 interaction Effects 0.000 description 7
238000002493 microarray Methods 0.000 description 7
238000013519 translation Methods 0.000 description 7
108020004705 Codon Proteins 0.000 description 6
230000004568 DNA-binding Effects 0.000 description 6
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
238000010171 animal model Methods 0.000 description 6
150000001557 benzodiazepines Chemical class 0.000 description 6
239000003184 complementary RNA Substances 0.000 description 6
230000006378 damage Effects 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
238000013461 design Methods 0.000 description 6
230000006870 function Effects 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
229910052740 iodine Inorganic materials 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
210000004153 islets of langerhan Anatomy 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
108091023037 Aptamer Proteins 0.000 description 5
102000011727 Caspases Human genes 0.000 description 5
108010076667 Caspases Proteins 0.000 description 5
102100038023 DNA fragmentation factor subunit beta Human genes 0.000 description 5
108010049207 Death Domain Receptors Proteins 0.000 description 5
102000009058 Death Domain Receptors Human genes 0.000 description 5
241000282326 Felis catus Species 0.000 description 5
208000021642 Muscular disease Diseases 0.000 description 5
201000009623 Myopathy Diseases 0.000 description 5
101000941356 Nostoc ellipsosporum Cyanovirin-N Proteins 0.000 description 5
108700008625 Reporter Genes Proteins 0.000 description 5
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
229940100198 alkylating agent Drugs 0.000 description 5
239000002168 alkylating agent Substances 0.000 description 5
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
108010006025 bovine growth hormone Proteins 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
230000000747 cardiac effect Effects 0.000 description 5
238000000423 cell based assay Methods 0.000 description 5
230000030833 cell death Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
108091008053 gene clusters Proteins 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000003384 imaging method Methods 0.000 description 5
230000001771 impaired effect Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
208000017169 kidney disease Diseases 0.000 description 5
238000005259 measurement Methods 0.000 description 5
210000003470 mitochondria Anatomy 0.000 description 5
230000002438 mitochondrial effect Effects 0.000 description 5
230000002093 peripheral effect Effects 0.000 description 5
238000003752 polymerase chain reaction Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
235000013930 proline Nutrition 0.000 description 5
238000000159 protein binding assay Methods 0.000 description 5
230000005855 radiation Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
229960001052 streptozocin Drugs 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000011830 transgenic mouse model Methods 0.000 description 5
238000010396 two-hybrid screening Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
241000272517 Anseriformes Species 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
108090000397 Caspase 3 Proteins 0.000 description 4
102100029855 Caspase-3 Human genes 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 4
238000000018 DNA microarray Methods 0.000 description 4
208000007342 Diabetic Nephropathies Diseases 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
108010051696 Growth Hormone Proteins 0.000 description 4
102000018997 Growth Hormone Human genes 0.000 description 4
108010040897 Microfilament Proteins Proteins 0.000 description 4
241000699660 Mus musculus Species 0.000 description 4
108010021466 Mutant Proteins Proteins 0.000 description 4
102000008300 Mutant Proteins Human genes 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
206010033307 Overweight Diseases 0.000 description 4
108010067902 Peptide Library Proteins 0.000 description 4
241000286209 Phasianidae Species 0.000 description 4
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
108091023040 Transcription factor Proteins 0.000 description 4
102000040945 Transcription factor Human genes 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
241000251539 Vertebrata <Metazoa> Species 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
230000001640 apoptogenic effect Effects 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
238000004166 bioassay Methods 0.000 description 4
230000008049 biological aging Effects 0.000 description 4
235000020934 caloric restriction Nutrition 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000002596 correlated effect Effects 0.000 description 4
125000004122 cyclic group Chemical group 0.000 description 4
230000007547 defect Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
230000000994 depressogenic effect Effects 0.000 description 4
238000009826 distribution Methods 0.000 description 4
230000001747 exhibiting effect Effects 0.000 description 4
206010061989 glomerulosclerosis Diseases 0.000 description 4
239000000122 growth hormone Substances 0.000 description 4
230000036541 health Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000003914 insulin secretion Effects 0.000 description 4
210000005228 liver tissue Anatomy 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
244000005700 microbiome Species 0.000 description 4
239000000178 monomer Substances 0.000 description 4
238000010172 mouse model Methods 0.000 description 4
238000007899 nucleic acid hybridization Methods 0.000 description 4
235000016709 nutrition Nutrition 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
230000002265 prevention Effects 0.000 description 4
238000007363 ring formation reaction Methods 0.000 description 4
238000005070 sampling Methods 0.000 description 4
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
238000007423 screening assay Methods 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000003160 two-hybrid assay Methods 0.000 description 4
229910052720 vanadium Inorganic materials 0.000 description 4
230000009278 visceral effect Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical group N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 3
241000251468 Actinopterygii Species 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
241000283707 Capra Species 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
102100032137 Cell death activator CIDE-3 Human genes 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
108020004394 Complementary RNA Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108010001515 Galectin 4 Proteins 0.000 description 3
102100039556 Galectin-4 Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
101000775558 Homo sapiens Cell death activator CIDE-3 Proteins 0.000 description 3
101000950965 Homo sapiens DNA fragmentation factor subunit beta Proteins 0.000 description 3
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 3
108010000521 Human Growth Hormone Proteins 0.000 description 3
102000002265 Human Growth Hormone Human genes 0.000 description 3
239000000854 Human Growth Hormone Substances 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
206010061216 Infarction Diseases 0.000 description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
108020005187 Oligonucleotide Probes Proteins 0.000 description 3
241001494479 Pecora Species 0.000 description 3
244000269722 Thea sinensis Species 0.000 description 3
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
210000003486 adipose tissue brown Anatomy 0.000 description 3
230000002411 adverse Effects 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000000090 biomarker Substances 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
150000004657 carbamic acid derivatives Chemical class 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
238000012790 confirmation Methods 0.000 description 3
235000020940 control diet Nutrition 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 3
208000033679 diabetic kidney disease Diseases 0.000 description 3
230000002124 endocrine Effects 0.000 description 3
210000003195 fascia Anatomy 0.000 description 3
239000000835 fiber Substances 0.000 description 3
235000019688 fish Nutrition 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000006377 glucose transport Effects 0.000 description 3
230000004190 glucose uptake Effects 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
201000001421 hyperglycemia Diseases 0.000 description 3
238000007901 in situ hybridization Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000007574 infarction Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
201000001119 neuropathy Diseases 0.000 description 3
230000007823 neuropathy Effects 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000002547 new drug Substances 0.000 description 3
239000002751 oligonucleotide probe Substances 0.000 description 3
230000008816 organ damage Effects 0.000 description 3
150000002894 organic compounds Chemical class 0.000 description 3
239000002245 particle Substances 0.000 description 3
208000033808 peripheral neuropathy Diseases 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
238000011002 quantification Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
210000003705 ribosome Anatomy 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
230000001629 suppression Effects 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
229910052721 tungsten Inorganic materials 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 2
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
206010000599 Acromegaly Diseases 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102100034691 Astrocytic phosphoprotein PEA-15 Human genes 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241001466804 Carnivora Species 0.000 description 2
102100026548 Caspase-8 Human genes 0.000 description 2
108090000538 Caspase-8 Proteins 0.000 description 2
206010057248 Cell death Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
101800001982 Cholecystokinin Proteins 0.000 description 2
102100025841 Cholecystokinin Human genes 0.000 description 2
241001454694 Clupeiformes Species 0.000 description 2
241000218631 Coniferophyta Species 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
241000195493 Cryptophyta Species 0.000 description 2
108020003215 DNA Probes Proteins 0.000 description 2
239000003298 DNA probe Substances 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000283086 Equidae Species 0.000 description 2
208000004930 Fatty Liver Diseases 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 2
108010001483 Glycogen Synthase Proteins 0.000 description 2
102000005548 Hexokinase Human genes 0.000 description 2
108700040460 Hexokinases Proteins 0.000 description 2
241001272567 Hominoidea Species 0.000 description 2
101000734668 Homo sapiens Astrocytic phosphoprotein PEA-15 Proteins 0.000 description 2
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
208000009773 Insulin Coma Diseases 0.000 description 2
208000031773 Insulin resistance syndrome Diseases 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
208000007976 Ketosis Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
241000283953 Lagomorpha Species 0.000 description 2
241000218922 Magnoliophyta Species 0.000 description 2
101100220687 Mus musculus Cidea gene Proteins 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 2
241000282320 Panthera leo Species 0.000 description 2
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
241000288906 Primates Species 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
238000002123 RNA extraction Methods 0.000 description 2
108700005075 Regulator Genes Proteins 0.000 description 2
208000017442 Retinal disease Diseases 0.000 description 2
206010038923 Retinopathy Diseases 0.000 description 2
108010077895 Sarcosine Proteins 0.000 description 2
206010040576 Shock hypoglycaemic Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010068542 Somatotropin Receptors Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
241001493546 Suina Species 0.000 description 2
229940100389 Sulfonylurea Drugs 0.000 description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
239000000370 acceptor Substances 0.000 description 2
239000012190 activator Substances 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
239000000556 agonist Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
238000012867 alanine scanning Methods 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
235000008206 alpha-amino acids Nutrition 0.000 description 2
150000001414 amino alcohols Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000003098 androgen Substances 0.000 description 2
230000003712 anti-aging effect Effects 0.000 description 2
229940127003 anti-diabetic drug Drugs 0.000 description 2
239000003472 antidiabetic agent Substances 0.000 description 2
238000003782 apoptosis assay Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003491 array Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
230000000035 biogenic effect Effects 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
244000309466 calf Species 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
239000000969 carrier Substances 0.000 description 2
108010042238 caspase-activated deoxyribonuclease Proteins 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
229940107137 cholecystokinin Drugs 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
230000010428 chromatin condensation Effects 0.000 description 2
239000002131 composite material Substances 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000010219 correlation analysis Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000000032 diagnostic agent Substances 0.000 description 2
229940039227 diagnostic agent Drugs 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
229960001484 edetic acid Drugs 0.000 description 2
239000012636 effector Substances 0.000 description 2
230000037149 energy metabolism Effects 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
229940125532 enzyme inhibitor Drugs 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000010195 expression analysis Methods 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000014101 glucose homeostasis Effects 0.000 description 2
229940096919 glycogen Drugs 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
108700015942 human G119R Proteins 0.000 description 2
102000054939 human G119R Human genes 0.000 description 2
150000001469 hydantoins Chemical class 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
230000003345 hyperglycaemic effect Effects 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000012528 insulin ELISA Methods 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
230000004140 ketosis Effects 0.000 description 2
210000003127 knee Anatomy 0.000 description 2
150000002611 lead compounds Chemical class 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229960003105 metformin Drugs 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
238000010208 microarray analysis Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
210000001087 myotubule Anatomy 0.000 description 2
208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
238000010397 one-hybrid screening Methods 0.000 description 2
230000010627 oxidative phosphorylation Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
229960003330 pentetic acid Drugs 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000005522 programmed cell death Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
VBUBYMVULIMEHR-UHFFFAOYSA-N propa-1,2-diene;prop-1-yne Chemical compound CC#C.C=C=C VBUBYMVULIMEHR-UHFFFAOYSA-N 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
230000005258 radioactive decay Effects 0.000 description 2
238000000163 radioactive labelling Methods 0.000 description 2
239000000376 reactant Substances 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000003938 response to stress Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000002689 soil Substances 0.000 description 2
108010033419 somatotropin-binding protein Proteins 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
230000002747 voluntary effect Effects 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 description 1
BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
KANAPVJGZDNSCZ-UHFFFAOYSA-N 1,2-benzothiazole 1-oxide Chemical class C1=CC=C2S(=O)N=CC2=C1 KANAPVJGZDNSCZ-UHFFFAOYSA-N 0.000 description 1
JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
IAIGWBZFHIEWJI-UHFFFAOYSA-N 1h-1,4-benzodiazepine-2,5-dione Chemical group N1C(=O)C=NC(=O)C2=CC=CC=C21 IAIGWBZFHIEWJI-UHFFFAOYSA-N 0.000 description 1
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
SOZJOEXYKMDOMP-UHFFFAOYSA-N 3,4,5,6-tetrahydroxypyran-2-one Chemical class OC=1OC(=O)C(O)=C(O)C=1O SOZJOEXYKMDOMP-UHFFFAOYSA-N 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
241001545522 Aguacate virus Species 0.000 description 1
239000012099 Alexa Fluor family Substances 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
244000099147 Ananas comosus Species 0.000 description 1
235000007119 Ananas comosus Nutrition 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000238421 Arthropoda Species 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
101100381862 Bacillus subtilis (strain 168) bmr3 gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
101150017888 Bcl2 gene Proteins 0.000 description 1
101001075376 Bos taurus Gamma-glutamyl hydrolase Proteins 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
102000009122 CCAAT-Enhancer-Binding Proteins Human genes 0.000 description 1
108010048401 CCAAT-Enhancer-Binding Proteins Proteins 0.000 description 1
101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
101710103504 CXXC-type zinc finger protein 1 Proteins 0.000 description 1
102100036168 CXXC-type zinc finger protein 1 Human genes 0.000 description 1
101100453921 Caenorhabditis elegans kin-29 gene Proteins 0.000 description 1
101100181137 Caenorhabditis elegans pkc-3 gene Proteins 0.000 description 1
101100425600 Caenorhabditis elegans samp-1 gene Proteins 0.000 description 1
101100481570 Caenorhabditis elegans tlp-1 gene Proteins 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000004039 Caspase-9 Human genes 0.000 description 1
108090000566 Caspase-9 Proteins 0.000 description 1
108090000624 Cathepsin L Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000218645 Cedrus Species 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
241000555825 Clupeidae Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
206010010305 Confusional state Diseases 0.000 description 1
244000241257 Cucumis melo Species 0.000 description 1
235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
102000003849 Cytochrome P450 Human genes 0.000 description 1
102100030497 Cytochrome c Human genes 0.000 description 1
108010075031 Cytochromes c Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
208000002230 Diabetic coma Diseases 0.000 description 1
206010012655 Diabetic complications Diseases 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
101100269980 Drosophila melanogaster aPKC gene Proteins 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
239000004243 E-number Substances 0.000 description 1
235000019227 E-number Nutrition 0.000 description 1
108700036061 EC 3.4.21.88 Proteins 0.000 description 1
VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
101710184259 Elongation factor 1-gamma Proteins 0.000 description 1
102100023362 Elongation factor 1-gamma Human genes 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
108010087894 Fatty acid desaturases Proteins 0.000 description 1
240000008168 Ficus benjamina Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
241000956293 Fulda Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000272496 Galliformes Species 0.000 description 1
206010060891 General symptom Diseases 0.000 description 1
206010056740 Genital discharge Diseases 0.000 description 1
206010018265 Gigantism Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
229940122853 Growth hormone antagonist Drugs 0.000 description 1
101710099093 Growth hormone receptor Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 1
101000664527 Homo sapiens Spastin Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108010071893 Human Immunodeficiency Virus rev Gene Products Proteins 0.000 description 1
102000013266 Human Regular Insulin Human genes 0.000 description 1
108010090613 Human Regular Insulin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010070070 Hypoinsulinaemia Diseases 0.000 description 1
206010021079 Hypopnoea Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
101710186630 Insulin-1 Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710176178 Kidney androgen-regulated protein Proteins 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
241000442132 Lactarius lactarius Species 0.000 description 1
102100038609 Lactoperoxidase Human genes 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
101710173438 Late L2 mu core protein Proteins 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
241000270322 Lepidosauria Species 0.000 description 1
241000283986 Lepus Species 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
101710196632 LexA repressor Proteins 0.000 description 1
241000209510 Liliopsida Species 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
244000070406 Malus silvestris Species 0.000 description 1
240000004658 Medicago sativa Species 0.000 description 1
235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
241000252067 Megalops atlanticus Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
102000002151 Microfilament Proteins Human genes 0.000 description 1
102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
241000237852 Mollusca Species 0.000 description 1
101100112373 Mus musculus Ctsm gene Proteins 0.000 description 1
101500025412 Mus musculus Processed cyclic AMP-responsive element-binding protein 3-like protein 1 Proteins 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
OLNLSTNFRUFTLM-UHFFFAOYSA-N N-ethylasparagine Chemical compound CCNC(C(O)=O)CC(N)=O OLNLSTNFRUFTLM-UHFFFAOYSA-N 0.000 description 1
YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
108010065338 N-ethylglycine Proteins 0.000 description 1
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
101100294752 Nectria sp ntnM gene Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 description 1
OZBZONOEYUBXTD-UHFFFAOYSA-N OOOOOOOOO Chemical compound OOOOOOOOO OZBZONOEYUBXTD-UHFFFAOYSA-N 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
108700043304 PKC-3 Proteins 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
102000052651 Pancreatic hormone Human genes 0.000 description 1
101800001268 Pancreatic hormone Proteins 0.000 description 1
241000282322 Panthera Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
241000283089 Perissodactyla Species 0.000 description 1
102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
241000218657 Picea Species 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
108010003541 Platelet Activating Factor Proteins 0.000 description 1
108091036407 Polyadenylation Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
229910052774 Proactinium Inorganic materials 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
101710188306 Protein Y Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241000220324 Pyrus Species 0.000 description 1
241000219492 Quercus Species 0.000 description 1
108010065868 RNA polymerase SP6 Proteins 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108010034634 Repressor Proteins Proteins 0.000 description 1
102000009661 Repressor Proteins Human genes 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
108010000605 Ribosomal Proteins Proteins 0.000 description 1
102000002278 Ribosomal Proteins Human genes 0.000 description 1
108091006300 SLC2A4 Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
102000018674 Sodium Channels Human genes 0.000 description 1
240000003768 Solanum lycopersicum Species 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
102100038829 Spastin Human genes 0.000 description 1
101100344811 Starmerella bombicola mdr gene Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
101100273705 Talaromyces islandicus cctN gene Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
241000592342 Tracheophyta Species 0.000 description 1
101710195626 Transcriptional activator protein Proteins 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
238000002679 ablation Methods 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
210000000593 adipose tissue white Anatomy 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
229960000451 ambenonium Drugs 0.000 description 1
OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
235000019513 anchovy Nutrition 0.000 description 1
229960003473 androstanolone Drugs 0.000 description 1
229940125713 antianxiety drug Drugs 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
230000005756 apoptotic signaling Effects 0.000 description 1
235000021016 apples Nutrition 0.000 description 1
101150010487 are gene Proteins 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
235000015241 bacon Nutrition 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000002599 biostatic effect Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
238000010504 bond cleavage reaction Methods 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
235000020827 calorie restriction Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
101150082996 cfl1 gene Proteins 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
229960004782 chlordiazepoxide Drugs 0.000 description 1
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
BJBUEDPLEOHJGE-IUYQGCFVSA-N cis-3-hydroxy-D-proline zwitterion Chemical compound O[C@H]1CCN[C@H]1C(O)=O BJBUEDPLEOHJGE-IUYQGCFVSA-N 0.000 description 1
235000021310 complex sugar Nutrition 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
RWZVPVOZTJJMNU-UHFFFAOYSA-N demarcarium Chemical compound C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 RWZVPVOZTJJMNU-UHFFFAOYSA-N 0.000 description 1
229960004656 demecarium Drugs 0.000 description 1
230000001904 diabetogenic effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000004980 dosimetry Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
229960003748 edrophonium Drugs 0.000 description 1
238000007336 electrophilic substitution reaction Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
241001233957 eudicotyledons Species 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
230000034725 extrinsic apoptotic signaling pathway Effects 0.000 description 1
230000006624 extrinsic pathway Effects 0.000 description 1
210000003054 facial bone Anatomy 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
239000000446 fuel Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
229940095884 glucophage Drugs 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000003673 groundwater Substances 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229940103471 humulin Drugs 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000035860 hypoinsulinemia Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
239000004026 insulin derivative Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000005976 liver dysfunction Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000013227 male C57BL/6J mice Methods 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000008267 milk Substances 0.000 description 1
230000006676 mitochondrial damage Effects 0.000 description 1
230000006667 mitochondrial pathway Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
210000003365 myofibril Anatomy 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
101150015830 nd1 gene Proteins 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229910052754 neon Inorganic materials 0.000 description 1
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
229960002362 neostigmine Drugs 0.000 description 1
LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
125000000371 nucleobase group Chemical group 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
108010087204 oncoimmunin-M Proteins 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229960004535 oxazepam Drugs 0.000 description 1
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004783 oxidative metabolism Effects 0.000 description 1
230000036407 pain Effects 0.000 description 1
239000004025 pancreas hormone Substances 0.000 description 1
229940032957 pancreatic hormone Drugs 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
244000045947 parasite Species 0.000 description 1
210000002990 parathyroid gland Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
235000021017 pears Nutrition 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
238000000554 physical therapy Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
244000000003 plant pathogen Species 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
235000021018 plums Nutrition 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
235000012015 potatoes Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229940095885 precose Drugs 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
PUIBPGHAXSCVRF-QHFGJBOXSA-N prostaglandin C1 Chemical compound CCCCC[C@H](O)\C=C\C1=CCC(=O)[C@@H]1CCCCCCC(O)=O PUIBPGHAXSCVRF-QHFGJBOXSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000022558 protein metabolic process Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000001303 quality assessment method Methods 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
235000019512 sardine Nutrition 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
238000007873 sieving Methods 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
210000001764 somatotrope Anatomy 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
210000002948 striated muscle cell Anatomy 0.000 description 1
238000011410 subtraction method Methods 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002352 surface water Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
150000003548 thiazolidines Chemical class 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
230000035922 thirst Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
208000021510 thyroid gland disease Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
238000012250 transgenic expression Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
238000004148 unit process Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Marine Sciences & Fisheries (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002557181A 2004-02-26 2005-02-24 Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de facon differentielle dans les cellules musculaires Abandoned CA2557181A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US54751204P	2004-02-26	2004-02-26
US60/547,512		2004-02-26
US57934204P	2004-06-15	2004-06-15
US60/579,342		2004-06-15
PCT/US2005/005596 WO2005082398A2 (fr)	2004-02-26	2005-02-24	Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires

Publications (1)

Publication Number	Publication Date
CA2557181A1 true CA2557181A1 (fr)	2005-09-09

Family

ID=34915602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002557181A Abandoned CA2557181A1 (fr)	2004-02-26	2005-02-24	Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de facon differentielle dans les cellules musculaires

Country Status (4)

Country	Link
EP (1)	EP1732582A2 (fr)
AU (1)	AU2005216922A1 (fr)
CA (1)	CA2557181A1 (fr)
WO (1)	WO2005082398A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2587790A1 (fr) *	2004-12-07	2006-06-15	Ohio University	Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ceux-ci sur la base de proteines exprimees differemment dans le serum
GB0512401D0 (en) *	2005-06-17	2005-07-27	Randox Lab Ltd	Method
EP1790664A1 (fr)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
CN102333889A (zh) *	2009-02-27	2012-01-25	韦尔瓦制药有限公司	基于基因表达特征的ⅱ型糖尿病的药物鉴别方案
WO2013167153A1 (fr)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Anticorps utiles dans le diagnostic du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2370134A1 (fr) *	1999-05-05	2000-11-09	Ohio University	Genes et proteines hepatiques pouvant etre regules par l'hormone de croissance, utilisations associees
WO2004092419A2 (fr) *	2003-03-31	2004-10-28	Ohio University	Diagnosis de l'hyperinsulinemie et du diabette de type ii et protection correspondante (i)

2005
- 2005-02-24 CA CA002557181A patent/CA2557181A1/fr not_active Abandoned
- 2005-02-24 AU AU2005216922A patent/AU2005216922A1/en not_active Abandoned
- 2005-02-24 WO PCT/US2005/005596 patent/WO2005082398A2/fr not_active Ceased
- 2005-02-24 EP EP05713932A patent/EP1732582A2/fr not_active Withdrawn

Also Published As

Publication number	Publication date
AU2005216922A1 (en)	2005-09-09
EP1732582A2 (fr)	2006-12-20
WO2005082398A2 (fr)	2005-09-09
WO2005082398A3 (fr)	2006-01-26

Publication	Publication Date	Title
Takashima et al.	2016	Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
US7786265B2 (en)	2010-08-31	Isolated antibodies against biologically active leptin-related peptides
CA2527957A1 (fr)	2005-01-06	Procedes de diagnostic et de traitement lies au vieillissement, en particulier au vieillissement du foie
CA2557181A1 (fr)	2005-09-09	Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de facon differentielle dans les cellules musculaires
WO2000023100A2 (fr)	2000-04-27	Genes et proteines destines a la prevention et therapie de maladies renales et de troubles associes
US20070142311A1 (en)	2007-06-21	Diagnosis of hyperinsulinemia and type II diabetes and protection against same
CN117750976A (zh)	2024-03-22	用于糖尿病以及并发病的新型治疗、诊断和检测的方法以及制剂
WO2006023121A1 (fr)	2006-03-02	Diagnostic d'hyperinsulinemie et de diabete de type ii et protection contre ceux-ci a base de genes differentiellement exprimes dans le tissu adipeux blanc (13)
KR20120061070A (ko)	2012-06-12	당뇨병 치료를 위한 ｍｇ２９를 조정하는 조성물 및 방법
WO2005046718A1 (fr)	2005-05-26	Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ces maladies sur la base de genes d'expression differentielle dans des cellules pancreatiques (12.1)
EP2619330B1 (fr)	2018-05-09	Procédés pour identifier des composés permettant d'augmenter l'expression ou l'activité de l'aspartyl aminopeptidase
WO2005110460A2 (fr)	2005-11-24	Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1)
WO2005005668A2 (fr)	2005-01-20	Methodes de diagnostic et de traitement se rapportant au vieillissement (8a)
WO2004092419A2 (fr)	2004-10-28	Diagnosis de l'hyperinsulinemie et du diabette de type ii et protection correspondante (i)
US20060240500A1 (en)	2006-10-26	Diagnosis of kidney damage and protection against same
Argall et al.	2021	Inherited Variants in SCARB1 Cause Severe Early-Onset Coronary Artery Disease
TWI250209B (en)	2006-03-01	A novel G protein-coupled receptor, GAVE8
US20050142561A1 (en)	2005-06-30	Intracellular signaling pathways in diabetic subjects
US20030119024A1 (en)	2003-06-26	Genes and proteins associated with T cell activation
HU230404B1 (hu)	2016-04-28	Hígításon alapuló gátlóhatást mérő módszer

Legal Events

Date	Code	Title	Description
2010-02-24	FZDE	Discontinued